Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Receivables - Net: 2010-2025

Historic Receivables - Net for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $118.0 million.

  • Myriad Genetics' Receivables - Net fell 6.13% to $118.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.0 million, marking a year-over-year decrease of 6.13%. This contributed to the annual value of $121.2 million for FY2024, which is 6.04% up from last year.
  • Myriad Genetics' Receivables - Net amounted to $118.0 million in Q3 2025, which was down 13.87% from $137.0 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Receivables - Net ranged from a high of $137.0 million in Q2 2025 and a low of $91.3 million during Q4 2021.
  • Moreover, its 3-year median value for Receivables - Net was $118.1 million (2024), whereas its average is $119.9 million.
  • The largest annual percentage gain for Myriad Genetics' Receivables - Net in the last 5 years was 39.21% (2021), contrasted with its biggest fall of 8.20% (2021).
  • Quarterly analysis of 5 years shows Myriad Genetics' Receivables - Net stood at $91.3 million in 2021, then increased by 11.28% to $101.6 million in 2022, then rose by 12.50% to $114.3 million in 2023, then grew by 6.04% to $121.2 million in 2024, then decreased by 6.13% to $118.0 million in 2025.
  • Its last three reported values are $118.0 million in Q3 2025, $137.0 million for Q2 2025, and $120.4 million during Q1 2025.